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Alzheimer’s disease (AD) is the most common neuro-
degenerative disorder associated to dementia in late
adulthood. Amyloid precursor protein, presenilin 1 and
presenilin 2 genes have been identified as causative
genes for familial AD, whereas apolipoprotein E e4 allele
has been associated to the risk for late onset AD.
However, mutations on these genes do not explain the
majority of cases. Mitochondrial respiratory chain (MRC)
impairment has been detected in brain, muscle, fibro-
blasts and platelets of Alzheimer’s patients, indicating a
possible involvement of mitochondrial DNA (mtDNA) in
the aetiology of the disease. Several reports have iden-
tified mtDNA mutations in Alzheimer’s patients, sug-
gesting the existence of related causal factors probably
of mtDNA origin, thus pointing to the involvement of
mtDNA in the risk contributing to dementia, but there is
no consensual opinion in finding the cause for impair-
ment. However, mtDNA mutations might modify age of
onset, contributing to the neurodegenerative process,
probably due to an impairment of MRC and/or transla-
tion mechanisms.
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Alzheimer’s disease (AD) (Alzheimer 1907) is the most com-
mon form of dementia, presenting a broad and hetero-
geneous range of symptoms, including progressive loss of
memory, cognitive/language impairment and behaviour dis-
turbances. Diagnosis can only be achieved by autopsy, com-
proving neuron loss and the presence of neurofibrillary
tangles (NFTs) and senile plaques (SPs) in brain tissue
(Terry & Katzman 1983), considered as the neuropathological
hallmarks of the disease. Nevertheless, it is clear that the
cellular pathways responsible for Alzheimer’s pathology are
complex in nature and extend beyond the production of
extracellular plaques of b-amyloid (Ab) aggregates and intra-
cellular NFTs (Chong et al. 2005).
Pathological mechanisms of AD
The exact mechanism underlying the aetiology of the disease
remains unknown. However, several hypotheses have been
raised to explain the pathological alterations observed
(recently reviewed by Pereira et al. 2005).
Loss of neurons and brain-impaired function occur in the
early phase of the disease and cause synaptic dysfunction,
leading to memory loss and cognitive impairment, two main
features of AD presentation (Walsh & Selkoe 2004a).
Amyloid-b (A-b) peptides aggregate in the extracellular
space forming the SPs.
Insoluble A-b is the major component of SPs, resulting
from the proteolysis of amyloid precursor protein (APP) by
g and b secretases. APP is a transmembrane glycoprotein
that undergoes proteolytic cleavage by g and a or b secre-
tases, respectively (Mattson 1997). A-b is a spontaneous
aggregating peptide variably comprised 37–43 amino acids,
the peptides 42–43 being the most toxic component of SPs
(Walker et al. 2005). According to the amyloid hypothesis, it
has been suggested that the accumulation of A-b peptides
results from the dysregulation of the production/processing
pathways, leading to AD-related neurodegeneration (Hardy &
Selkoe 2002). But, it is also possible that A-b toxicity occurs
in consequence of more fundamental pathological changes
and may even play a protective role in the diseased brain
(Lee et al. 2004), raising some controversial points to this
issue. Some recent data contributed to the revision of the
amyloid cascade hypothesis (Golde 2003; Hardy & Selkoe
2002), suggesting that soluble forms of A-b (Kuo et al.
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1996), such as oligomers (Walsh & Selkoe 2004b), may play a
pivotal role in the neurodegenerative process leading to AD.
Another mechanism contributing to AD pathology involves
the hyperphosphorylation of tau, a microtubule-associated
protein. Aggregation of hyperphosphorylated tau occurs in
several neurodegenerative disorders, including AD, affecting
microtubule stability and polymerization, due to conforma-
tional changes (see Iqbal et al. 2005 for review).
One of the most comprehensively studied systems cur-
rently accepted to be implicated in AD phenotype involves
mitochondria dysfunction and oxidative stress. It has been
shown that mitochondria degeneration occurs early in the
course of the disease (Hirai et al. 2001). Additionally, mito-
chondrial energy metabolism key enzymes, with special
attention to cytochrome c oxidase (Castellani et al. 2002),
have been shown to be severely affected in AD (Blass 2001;
Eckert et al. 2003). More recently, it has also been reported
that genes coding for subunits of the oxidative phosphoryla-
tion system are differentially expressed in patients with AD,
suggesting that mtDNA defects may be responsible for the
heterogeneity of the phenotype observed in AD patients
(Manczak et al. 2004).
Several lines of evidence from the literature point towards
the fact that the proteolytic processing of A-b is synergisti-
cally related with impaired energy metabolism (reviewed in
Pereira et al. 2005). It has also been shown that accumula-
tion of APP in mitochondria, in a transmembrane-arrested
form, causes mitochondrial dysfunction and impairment of
energy metabolism, demonstrating that APP is targeted to
neuronal mitochondria under some physiological and path-
ological conditions (Anandatheerthavarada et al. 2003),
including AD. The mechanism by which A-b induces mito-
chondrial dysfunction appears to involve abnormal reactive
oxygen species (ROS) production, emphasized by the fact
that most of the MRC complexes are susceptible to either
A-b or ROS (Arias et al. 2002; Cardoso et al. 2004b; Casley
et al. 2002; Pereira et al. 1998). Evidence has been presented
suggesting a role for mitochondrial dysfunction in upstream
events predisposing to neurodegeneration, and in down-
stream events accelerating cell dysfunction and loss
(Byrne 2002), with implications to Alzheimer’s pathology.
The defective energy production and increased oxygen
radicals may induce mitochondria-dependent cell death
because damaged mitochondria are unable to maintain the
energy demands of the cell (Zhu et al. 2004).
Moreover, recent data propose that mitochondrial energy
metabolism is impaired by the expression of mutant APP
and/or A-b and that the up-regulation of mitochondrial
genes is a compensatory response, with important implica-
tions for the understanding of the mechanism of A-b toxicity
in AD and for developing therapeutic strategies for the
disease (Reddy et al. 2004). Recent studies in transgenic
mice overexpressing mitochondrial Ab-binding alcohol
dehydrogenase (ABAD), ordinarily a contributor to metabolic
homeostasis, provide additional evidence for ABAD–A-b
interaction leading to oxidative stress and mitochondrial
dysfunction (Lustbader et al. 2004) and that ABAD has
the capacity to become a pathogenic factor in an A-b–rich
environment (Yan & Stern 2005).
Because mitochondria are the major site of free radical
production in cells, they are also a primary target for oxidative
damage and subsequent dysfunction (Sullivan & Brown
2005). Furthermore, mitochondrial genome (mtDNA) appears
to be more susceptible to accumulating oxidative damage
(compared with nuclear DNA) due to its proximity to ROS
production (Zhu et al. 2004), and abnormalities in mtDNA
may be a major cause of abnormal ROS production in AD
(Migliore et al. 2005) due to malfunction of respiratory chain
subunits.
Mitochondria are the primary source of cellular oxidants,
taking into account that 2–5% of O2 is not completely
reduced to H2O at the electron transport chain and, there-
fore, a prime target of cumulative oxidative damage. Damage
to mitochondrial proteins and mtDNA would be expected to
decrease mitochondrial bioenergetics and efficiency (Sullivan
& Brown 2005). The underlying mechanism of abnormal
mitochondrial ROS production is the altered redox potential
of MRC carriers (due to hyperpolarization of mitochondrial
membrane) and an increase in ubisemiquinone anion half-life
time, resulting in slower electron transport, producing inter-
mediates that stay reduced longer, thus increasing the
chance that the electrons can escape to molecular oxygen,
originating ROS (Sullivan & Brown 2005).
When the antioxidant defences in the cell are not able to
withdraw its effects, oxidative stress occurs and damage to
bio-molecules (proteins, lipids, nucleic acids) take place
(Boveris et al. 1972; Pereira et al. 2001). Several oxidative
stress markers have been found in different types of sam-
ples (including brain, urine, plasma or CSF) from AD patients
(Abe et al. 2002; Butterfield et al. 2001; Gibson & Huang
2002; Migliore et al. 2005; Pratico` et al. 2000, 2002), and data
have been reported demonstrating that antioxidants’ treat-
ment delays the progression of the disease (Kontush &
Schekatolina 2004; Sano et al. 1997; Vin˜a et al. 2004, for
reviews).
The fact that abnormal mitochondria contribute to oxida-
tive stress in AD brain is supported by the correlation found
between mtDNA alterations and the extent of nucleic acid
injury in cytoplasm (Hirai et al. 2001; Zhu et al. 2004), sug-
gesting a temporal relationship between neuronal oxidative
damage and mitochondrial abnormalities (Hirai et al. 2001).
On the contrary, oxidative stress may be directly involved
in abnormal APP processing. In fact, it has been recently
demonstrated that A-b accumulation is increased in trans-
genic mice harbouring alterations in brain oxidative status
(Apelt et al. 2004). Moreover, A-b peptides have been sug-
gested to be a source of oxidative stress in AD (Pereira et al.
2005), and it has been shown that A-b inhibits MRC activity
and induces increased ROS production (Mark et al. 1997;
Casley et al. 2002).
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Data reported by Sung and colleagues (Sung et al. 2004),
showing that vitamin E may reduce A-b levels and amyloid
deposition in a transgenic model of AD, support the hypo-
thesis that oxidative stress is an important early event in AD
pathogenesis, and antioxidant therapy may be beneficial only
at this stage of the disease process.
Recently, Pratico` (2005) predicted the two possible sce-
narios concerning the relevance of oxidative stress hypo-
thesis in AD pathology: (1) neuronal degeneration is the
consequence of an oxidative stress response to SPs and
NFTs rather than to generate these lesions per se; (2) oxida-
tive stress is an early event triggering the formation of SPs
and NFTs, which in turn activate more oxidative reactions
that drive a self-sustained ‘autodestructive’ process and the
relentless progression of AD. However, the question
whether oxidative stress is an early component in the path-
ogenesis of the disease or a common final step of the
neurodegenerative process in AD remains unclear.
The pathways thought to be involved in AD pathology also
include alterations in metal ion and calcium homeostasis. It
has been shown that copper, iron and zinc have the capacity
to bind A-b, accelerating its aggregation and enhancing toxi-
city, possibly by increasing oxidative stress (Castellani et al.
2004; Mattson 2004a, 2004b; Moreira et al. 2000; Rogers &
Lahiri 2004). The accumulation of the redox-active metals,
iron and copper, may be a source of ROS, which are in turn
responsible for oxidative stress observed in AD (Pereira et al.
2005).
It is currently accepted that calcium homeostasis disruption
plays an important role in synaptic dysfunction and neuro-
degeneration occurring in AD (LaFerla 2002; Mattson & Chan
2003). Recent data suggest that A-b is capable of being directly
incorporated into cell membranes, forming calcium-permeable
ion channels, and causing abnormal intracellular calcium levels
(Kawahara 2004), compromising the activity of calcium-depen-
dent proteins (O’Day & Myre 2004). However, amyloid pep-
tides have been described as being able to both alter the
dynamics of intracellular calcium ion signals or have no effect
at all, and it is almost impossible to extract an intelligible picture
fromwhich to draw conclusions, probably due to the variety of
preparations used (Canevari et al. 2004).
The fact that the main genetic risk factor associated to AD
codes for apolipoprotein E (APO E), the main cholesterol
carrier in the brain, called the attention to the involvement
of cholesterol dyshomeostasis, playing a role in the disease.
APO E regulates cholesterol distribution in the brain; in add-
ition, both APO E and cholesterol, are co-localized in mature
SPs, further supporting their involvement in plaque formation
(Burns et al. 2003; Mori et al. 2001). Even without unifying
results, most studies suggest that an increased content of
cholesterol in the brain correlates with an increased risk of
developing AD (Vance et al. 2005). Moreover, transgenic
mice experiments revealed that a high cholesterol diet
increased brain cholesterol levels and accelerated deposition
of A-b (Howland et al. 1998; Shie et al. 2002).
There is considerable evidence that endoplasmic reticulum
(ER) dysregulation is involved in neuronal death occurring in
AD, through the inhibition of protein glycosylation, perturba-
tion of calcium homeostasis and reduction of disulphide
bonds that provoke accumulation of unfolded protein in the
ER, called ‘ER stress’ (Katayama et al. 2004). Dynamic cal-
cium changes within the ER are implicated in the regulation
of many cellular functions, from rapid signalling to long-
lasting adaptive responses, determining the cell fate
(Verkhratsky & Toescu 2003). It has been also proposed
that A-b can directly mediate ER stress responses and
apoptosis (Pereira et al. 2004). Additionally, ER stress and
mitochondrial dysfunction might cooperatively regulate
apoptotic-signalling cascades, pointing to ER stress as a
key event in triggering and mediating neuronal death in AD
(Takuma et al. 2005).
It has been observed that the neurotransmission systems
impairment, particularly affecting cholinergic neurons, is one
of the earliest pathological events in AD. In fact, it has been
shown that acetylcholinesterase (AChE) activity, responsible
for acethylcholine hydrolysis, was largely reduced, together
with neuronal loss occurring in the brain of AD patients
(Candy et al. 1983). Additionally, it has been demonstrated
that A-b may increase AChE activity (Fodero et al. 2004), and
conversely, it has been suggested that this enzyme can
induce A-b aggregation (recently reviewed by Inestrosa
et al. 2005). It has been recently found that increased AChE
expression may impair glutamatergic neurotransmission
(Dong et al. 2004). Several authors have provided further
evidences that other neurotransmission pathways may be
involved in AD, namely alterations in glutamatergic function
and serotonin system. Evidence exists showing that gluta-
mate-mediated excitotoxicity may contribute to the synaptic
impairment observed in AD, particularly the altered expres-
sion and pharmacology of glutamate receptors and transpor-
ters in pathologically susceptible brain regions (see
Tannenberg et al. 2004 for review). The role of serotonin in
ageing and related disorders, such as AD (Meltzer et al.
1998), shows that serotoninergic dysfunction (Terry et al.
1991) is potentially responsible for a significant portion of
the behavioural aspects of the disease, reinforcing the earlier
observation that 5HTR2A-binding sites are diminished in
post-mortem brain of AD patients. Furthermore, recent in
vitro and in vivo pharmacological and biochemical studies,
showing the involvement of 5-HT4 receptors in cognitive
processes and the APP processing, have been presented
(Maillet et al. 2004), stressing out the importance of seroto-
ninergic neurotransmission dysfunction in AD.
Epidemiological data show that sex-specific incidence of
AD is higher in women than men, suggesting the involve-
ment of oestrogen and other hormones in the pathophysio-
logical aspects of the disease. Accordingly, oestrogen has
become the primary focus of research in this field. Both
oestrogen concentrations, ranging from physiological to
pharmacological, are neuroprotective in a variety of in vivo
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and in vitro models of AD, as well as in reducing key neuro-
pathologic features of the disease (Simpkins et al. 2005).
However, inconclusive data regarding oestrogen-replacement
therapy (recently reviewed by Gleason et al. 2005) have led
to further investigate the role of other hormones in AD
pathogenesis (Webber et al. 2004). It has been recently
proposed that the increase in gonadotropin hormones levels,
and not the decrease in steroid hormones production follow-
ing menopause/andropause, may be a primary causative
factor for AD development (Casadesus et al. 2005; Webber
et al. 2005).
Studies demonstrating that non-steroidal anti-inflammatory
drugs significantly reduce the risk of developing AD suggest
the involvement of inflammatory response in AD patho-
genesis (Stewart et al. 1997; reviewed by Tuppo & A´rias
2005).
Damaged neuronal cells release cytokines, chemokines
and acute phase/complement proteins, possibly activating
microglia cells and astrocytes for an inflammatory response,
with up-regulation of inflammatory mediators (recently
reviewed by Tuppo & A´rias 2005). Data available from litera-
ture point to the involvement of ROS and reactive nitrogen
species in the microglia response during the neuroinflamma-
tion process (reviewed in Emerit et al. 2004). On the con-
trary, chronically activated glia associated with amyloid
plaques might contribute to neuronal dysfunction in AD
through the generation of neuroinflammatory molecules.
APO E, associated with amyloid plaques, has been hypothe-
sized to serve an anti-inflammatory role in the CNS through
its ability to modulate Ab-induced glial activation. Guo et al.
(2004) provided evidence supporting that A-b stimulation of
glial APO E limits neuroinflammation, but overproduction of
APO E by activated glia might exacerbate inflammation. In
addition, the observation that apo e4 isoform has more
robust pro-inflammatory activity than apo e3 provides a
mechanistic link between the APO E e4 allele and AD, and
suggests potential apo E-based therapeutic strategies (Guo
et al. 2004).
Furthermore, A-b itself may act as a pro-inflammatory
agent (Franciosi et al. 2005), and recent evidence suggests
that A-b oligomers induce a profound, early inflammatory
response, whereas fibrillar A-b shows a slighter increase of
pro-inflammatory response, consistent with a more chronic
form of inflammation (White et al. 2005).
However, the role that neuroinflammation plays in AD is
not fully clarified, and a better understanding of inflammatory
response occurring in disease progression is needed to
improve research in designing therapy specifically targeted
against the inflammatory processes (Tuppo & Arias 2005).
Finally, an extensive research in the last few years has
been focusing on cell death occurring in AD, particularly by
apoptosis. A large amount of data support that A-b may lead
to neuronal apoptosis (reviews in Pereira et al. 2004; Takuma
et al. 2005). Several lines of evidence demonstrate that A-b
peptides activate intracellular apoptosis pathways leading to
neuronal cell death, through mitochondrial dysfunction and
ER stress (Takuma et al. 2005) and also mediated by cell
membrane death receptor activation (Dickson 2004; Li et al.
2004).
Mitochondrial dysfunction is thought to be relevant in AD
not only through the abnormal generation of ROS but also
through the release of molecules that may initiate apoptotic
cell death pathways, such as cytochrome c (Morais Cardoso
et al. 2002). However, the precise molecular mechanisms
underlying mitochondrial dysfunction and ER stress in neu-
ronal cell death and neurodegeneration remain unknown
(Takuma et al. 2005).
Genetics of AD and APP
Several genetic factors have been associated to AD (Lendon
et al. 1997). It has been demonstrated that the presence of
the APO E e4 allele accounts for the risk of developing the
disease. APO E is a polymorphic protein with three common
isoforms – apo e2, apo e3 and apo e4 – coded by three
alleles – e2, e3 and e4 – at chromosome 19. APO E e4 appears
to confer substantial risk for late-onset AD, either sporadic or
familial (Saunders et al. 1993). Furthermore, mutations in the
APP (St George-Hyslop et al. 1987) and presenilin (PS1 and
PS2 ) (St George-Hyslop et al. 1992; van Broeckhoven et al.
1992) genes were shown to be responsible for a fraction of
the familial forms of AD (Levy-Lahad et al. 1995), with a
mutation frequency of 18–50% in autosomal dominant early
onset AD (Rademakers et al. 2003). The number of patho-
genic mutations identified in the genes associated to the
familial forms of AD is now over 170 (144 for PS1; 18 for
APP and 10 for PS2 ) (AD Mutation Database http://
www.molgen.ua.ac.be/ADMutations/default.cfm). Extensive
cell biology research in the last decade raised the hypothesis
that alterations of these genes cause AD through a common
biological pathway, resulting in an abnormal APP metabolic
processing (Rademakers et al. 2003).
Recently, transgenic mice have been investigated for
studying the influence of the above-mentioned mutations in
vivo. Mice overexpressing mutant AD-related proteins exhi-
bit many of the neuropathological and behavioural features of
the human disease. Transgenic animals have been created
that express mutations in the APP, PS1 and PS2 genes,
and in APP mouse models, an age-related accumulation of
A-b-containing neuritic plaques have been described in the
hippocampus and cerebral cortex, the activation of astro-
cytes and microglial cells (German & Eisch 2004). On the
contrary, dramatic changes in A-b 42/40 levels have been
observed in animals carrying PS2 mutations (Walker et al.
2005). The animal models of AD have also been used to
develop and test treatments that reduce brain levels of the
A-b 42 peptide (German & Eisch 2004), leading to the devel-
opment of novel therapeutic strategies (Selkoe 2004; Walsh
& Selkoe 2004a).
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Despite the high number of pathogenic mutations of the
above-mentioned genes identified in AD patients, which
have been associated with an alteration of APP/A-b meta-
bolic processing, they do not explain all AD cases.
A substantial body of evidence, indicating that distur-
bances of energy metabolism may play a fundamental role
in AD, suggests that a mitochondrial location for a ‘mechan-
istic bottleneck’ in the neurodegenerative cascade of the
disorder should be considered (Davis et al. 1995; Lee &
Wei 1997).
APP metabolic processing in AD
Altered metabolic processing of APP, including the aggrega-
tion of A-b peptide (Hardy & Selkoe 2002) and, more
recently, soluble protein aggregates – oligomers (Walsh &
Selkoe 2004b), have been considered the central mechan-
isms underlying neuronal degeneration occurring in AD [mod-
ified A-b cascade hypothesis, reviewed in (Pereira et al.
2005; Wirths et al. 2004)]. Nevertheless, the direct link
between A-b production and neuronal death has not been
clearly established. However, there is evidence that oxidative
stress promotes A-b generation and that hydrogen peroxide
is likely to mediate A-b toxicity (Pereira et al. 2001).
Several lines of evidence support the hypothesis that A-b
toxicity is mediated by ROS (Pereira et al. 2001); the first
evidence of this mechanism/pathway has been demon-
strated by the rescue of PC12 cells from A-b injury with
antioxidants, including vitamin E (Behl et al. 1992).
Furthermore, it was shown that A-b might induce membrane
lipid peroxidation and damage of intracellular membrane sys-
tems (Behl et al. 1994a), and the toxic effects were pre-
vented by antioxidants (Behl et al. 1994b). A direct
evidence of oxidative damage conducted using A-b toxicity,
in cultured neurons, was later obtained (Harris et al. 1995).
The involvement of oxidative stress in AD has been recently
reviewed, suggesting that A-b can also induce oxidative
changes on its way to brain deposition, rendering nerve
cells more vulnerable to additional insults (Behl 2005).
Nevertheless, the precise molecular mechanisms and the
pathophysiological impact of A-b-mediated oxidative stress
on the development of AD require further investigation.
Data from literature point towards the involvement of
mitochondrial dysfunction in A-b-induced toxicity and the
role of mitochondria in A-b-triggered apoptosis (Cardoso
et al. 2001; Mark et al. 1996; Pereira et al. 2004).
A reduced cytochrome c oxidase (COX) activity in AD
patients’ platelets has been observed (Cardoso et al.
2004a), and it was demonstrated that functional mitochon-
dria are required for A-b toxicity (Cardoso et al. 2001). In
contrast to NT2 rhoþ (normal content of mitochondria,
mtDNA), rho-0 cell (devoided of mtDNA, see King & Attardi
1989) viability was not affected by exposure to A-b, suggest-
ing that a functional mitochondrial respiratory chain (MRC) is
required for A-b toxicity. NT2 cells exposed to A-b were
shown to release cytochrome c with subsequent activation
of caspase 3, whereas rho-0 cells, which maintained mito-
chondrial membrane potential, demonstrated no cytochrome
c release or caspase activation upon A-b exposure. A reduc-
tion of COX activity and a decrease in ATP levels have been
found in AD cybrids, obtained by the fusion of rho-0 cells
with AD patients’ platelets, pointing to mtDNA involvement
in AD pathogenesis. When these cell lines were exposed to
A-b 1-40, a significant mitochondrial membrane depolariza-
tion, an increase in cytochrome c release and an elevated
caspase 3 activity were also observed (Cardoso et al. 2001).
Mitochondria seem to play a central role as a target for A-b
peptides (Moreira et al. 2001), either as a cause or as an
enhancing A-b toxicity (Cardoso et al. 2005). Furthermore,
increased levels of 8-hydroxy-20deoxyguanosine (8-OHdG),
evaluated as a marker of mtDNA oxidation, were found in
the brain of AD patients (Mecocci et al. 1994).
Hirai et al. (1991) have elegantly shown that damaged
mtDNA in AD brain is restricted to neurons vulnerable to
death, meaning that, although the increase is striking on a
per-cell basis, when seen in the context of brain tissue, the
change is very selective. This selective neuronal vulnerability
is also observed for oxidative damage, suggesting that a
relationship exists between the two phenomena. However,
several studies have demonstrated mitochondrial abnormal-
ities in non-neuronal tissues of AD patients (for example
Blass & Gibson 1991; Trimmer et al. 2000).
The particular characteristics of mtDNA, including an
increased susceptibility to oxidative damage and a higher
rate of ROS-induced mutations (Schon 2000), render this
genome as a potential target for oxidative injury.
Accordingly, the pathological pathway triggered by A-b
might include the increase in mtDNA mutations, possibly
causing MRC impairment, which could be used as a marker
of AD. Mitochondrial dysfunction has been reported to alter
APP processing, leading to increased intracellular A-b accu-
mulation (Beal 2004). mtDNA somatic mutations may confer
increased sensitivity to A-b toxicity or may contribute to
alterations in APP/A-b normal metabolic processing. In add-
ition, Khan et al. (2000), in a study evaluating A-b peptides’
secretion by cybrid cells containing ‘AD mitochondrial
genes’, demonstrated that mtDNA genes from AD patients
are responsible for cellular oversecretion of A-b peptides.
These findings implicate mitochondrial genetic abnormalities
as contributing to pathogenic amyloid metabolism in sporadic
AD, and A-b oversecretion would serve a critical secondary
role in the pathogenesis of the disease.
Accordingly, it can be hypothesized that cells may survive
to a certain level of A-b buildup but then succumb as A-b
further inhibits COX and possibly increases ROS production.
Finally, those authors propose that mtDNA defects and A-b
overproduction are etiologically intertwined, and that both
would be necessary for the cell death and cognitive impair-
ment that define this disease.
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Mitochondrial DNA mutations and risk for AD
Mutations of mtDNA may cause a progressive decline in
tissue output that could precipitate the onset of degenerative
diseases in individuals harbouring inherited deleterious muta-
tions. Thus, bioenergetic defects resulting from mtDNA
mutations may be a common cause of human degenerative
diseases, including AD (Brown & Wallace 1994; DeVivo
1993; Graeber et al. 1998; Hutchin et al. 1997; Wallace
1992). Moreover, impaired mitochondrial function caused
by mtDNA damage may render brain cells more susceptible
to oxidative injury and thereby provide a mechanism by
which systemic or environmental factors could influence
the course of the disease (de la Monte et al. 2000).
In 1992, Lin and colleagues identified a G-A transition and a
G-T transversion, both at nucleotide 5460 of mtDNA NADH
dehydrogenase subunit 2 gene, in AD patients, which were
not confirmed by Edland et al. (2002), Janetzky et al. (1996),
Ko¨sel et al. (1994) and Petruzzella et al. 1992). Later,
Shoffner et al. (1993) reported four variants (nucleotides
3196, 3397, 4336 and 956-965 insertion), having special
importance the tRNA(Gln) alteration at position 4336 that
modifies a moderately conserved nucleotide. Hutchin and
Cortopassi (1995), Egensperger et al. (1997) and Edland
et al. (2002) confirmed the presence of this tRNA variant in
AD patients, whereas Wragg et al. (1995) and Tysoe et al.
(1996) did not observe this association. Furthermore, Davis
et al. (1997) found specific missense mutations in mitochon-
drial cytochrome oxidase subunit 1 and subunit 2 genes that
appeared to be associated with late-onset AD. However,
Hirano et al. (1997) provided evidence that the method
employed by Davis et al. resulted in the coamplification of
nuclear mtDNA pseudogenes.
A point mutation 16390 (C-T), located at the control region
of the mtDNA, was reported to be two- to threefold more
frequent in AD brain compared with normal brain (Chang
et al. 2000). The same authors provided evidence for no
significant changes in 4977-kb deletion in the same samples
but observed regional variance in the distribution frequency
of this alteration. Two other mtDNA variants (G8206T and
A8224T) have been reported in one AD patient’s blood cells,
located at the gene coding for subunit 2 of complex IV (Qiu
et al. 2001), reinforcing complex IV impairment, but COX
activity has not been evaluated. In 2002, Lin and colleagues
reported for the first time a quantification of the aggregate
burden of point mutations in AD brain mtDNA. They have
found that although the level of any one individual mutation is
low, the aggregate burden of somatic mtDNA point muta-
tions in AD brains is high, and the accumulation of these
mutations correlates with a decrease in COX activity (Lin
et al. 2002). The mutations/polymorphisms found so far,
associated to AD, are summarized in Table 1.
mtDNA deletions have also been investigated in AD
patients, but there is no consensus concerning this issue.
Blanchard et al. (1993) reported no significant differences in
deleted/undeleted mtDNA (common deletion, 4977 bp) con-
tent comparing AD cases with age-matched controls, con-
sistent with findings from other authors (Chang et al. 2000).
On the contrary, other authors have found significantly
increased levels of the same deletion in AD brain (Corral-
Debrinski et al. 1994; Hamblet & Castora 1997).
We have recently reported mtDNA variants in two
AD patients: in one patient two already known mtDNA
modifications (3197 T-C and 3338 T-C) were found and a
novel mutation (3199 T-C) was identified (Grazina et al.
2005). A significantly higher frequency of the T3197C poly-
morphism was also detected in AD patients (Table 2) as well
as an elevated frequency of e4 allele. Most of the cases
having the 3197C variant, presented the e3e3 genotype. We
have identified three homoplasmic mtDNA variants in 14 AD
patients (3197C, 3199C and 3338C) and three
control subjects (3197C), by studying 129 AD patients and
125 normal subjects, affecting both 16S rRNA (3197C,
3199C) and mtDNA ND1 (3338C) genes. No positive cases
were found for 3196 position, in both patients and control
group.
The 3196A variant was found by Shoffner et al. (1993) in
one late-onset AD patient, in a population of 73 individuals,
and it was also described in an Asian control (homoplasmic).
The fact that it was heteroplasmic in the patient suggested a
new mutation, but by the fact of being found in only one
patient precludes its pathological significance (Shoffner et al.
1993). The search for this mutation in Japanese AD patients
did not show any positive case among 92 sporadic AD sub-
jects (Tanno et al. 1998), similar to what occurred in our 129
AD patient subset. This variant is also absent in patients
suffering from inclusion-body myositis (Kok et al. 2000).
Another alteration at this position (G-T) has been recently
described in a patient suffering from dilated cardiomyopathy
(Ruppert et al. 2004).
The T-C 3197 transition at the 16S rRNA mtDNA gene,
reported earlier in one of our AD patients (Grazina et al.
2005), had been previously described (Hess et al. 1995) in a
patient with ischaemic colitis and in AD, PD, AD þ PD
patients and Caucasian controls (Brown et al. 1996) as a
polymorphism. This polymorphism was also described by
Sternberg et al. (1998), Arbustini et al. (1998), Klemm et al.
(2001) and Vives-Bauza et al. (2002) in control subjects and in
patients with mitochondrial disorders, dilated cardiomyopa-
thy, maternal diabetes mellitus and PD patients, respectively.
The T-C 3199 transition was described for the first time by
our group (Grazina et al. 2005). The two patients having the
variants 3197C þ 3338C and 3199C (Grazina et al. 2005)
presented an e3e3 genotype at APO E gene, as the majority
of the cases having the 3197C variant, in accordance to what
had been described by Egensperger et al. (1997) in an AD
patient harbouring the A4336G mtDNA mutation.
If the 3197 T-C alteration is weakly conserved among
hominoid primates (Fig. 1) and consensually considered a
polymorphism, reported as associated to haplogroup U5,
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present in European populations (Herrnstadt et al. 2002), this
assumption may not be true for the nucleotide change at
position 3338. This modification was found by sequencing
analysis only in one hypertrophic cardiomyopathy patient
(Obayashi et al. 1992; Ozawa et al. 1991), in one multiple
sclerosis control subject (Chalmers et al. 1995), in one
Parkinson’s patient (Ko¨sel et al. 1998) and in our
Alzheimer’s patient (Grazina et al. 2005). Meanwhile, an
absence of Rsa I cleavage site was found in several samples
at nucleotide 3337 (Macaulay et al. 1999). This may be due to
a change at nucleotide 3338 but, as Rsa I recognizes the
same nucleotide sequence as Csp 6I, any of the four nucleo-
tides (3337, 3338, 3339 and 3340) may have a change that
causes the absence of cleavage, because there was no
sequencing confirmation of those results. Besides, this is a
much-conserved nucleotide among the hominoid primates
(Fig. 1) as well as nucleotides 3339 and 3340, which does
not occur with nucleotide 3337 because in Pongo pygmaeus
(orangutan) there is an A instead of a G in the DNA sequence
and a methionine instead of a valine in the ND1 protein
(Fig. 1). It is quite clear that, even with a group of controls
that does not cover all the population, we are facing an
alteration at nucleotide 3338 with a lower frequency. The
nucleotide change at position 3199 of the 16S rRNA
mtDNA gene found in another patient occurs in a moderately
conserved nucleotide in hominoid primates because in Pan
paniscus (bonobo) and P. pygmaeus (orangutan), there is a C
instead of a T (Fig. 1). On the contrary, at position 3196,
there is a G in Homo Sapiens, but there is an A in the other
species analysed. It is possible that 3196A variant may repre-
sent some evolutionary advantage or that it has some pro-
tective role. Moreover, we cannot exclude that there is an
interaction between APO E genotype and mtDNA altera-
tions, or that in patients with an e3/e3 genotype, there is a
Table 1: Summary of mutations/polymorphisms found in AD (modified from www.mitomap.org)
mtDNA variant Mutation type Affected gene Amino acid change References
146 (T-C) SM D-LOOP NC Unpublished
(www.mitmap.org)
414 (T-C) SM D-LOOP NC Unpublished
(www.mitmap.org)
477 (T-C) SM D-LOOP NC Unpublished
(www.mitmap.org)
956-965 (insertion) PM 12S RNA NC Shoffner et al. 1993
3196 (G-A; G-C) PM 16S rRNA NC Shoffner et al. 1993;
Tanno et al. 1998;
Wallace et al. 1992;
3197 (T-C) P 16S rRNA NC Grazina et al. 2005
3199 (T-C) P 16S rRNA NC Grazina et al. 2005
3338 (T-C) P ND1 Valine-Alanine Grazina et al. 2005
3397 (A-G) PM/P ND1 Methionine-Valine Brown et al. 1996;
Shoffner et al. 1993;
Tanno et al. 1998;
Wallace et al. 1992;
1995; Brown et al.1996;
4336 (T-C) PM tRNA Gln NC Cortopassi & Hutchin 1994; Coskun et al. 2004;
Edland et al. 2002; Egensperger et al. 1997;
Hutchin & Cortopassi 1995; Kok et al. 2000;
Shoffner et al. 1993; Tanno et al 1998;
Tysoe et al. 1996; Wallace et al. 1992;
Wragg et al. 1995;
4580 (G-A) P ND2 Silent (methionine) Kok et al. 2000;
5460 (G-A; G-T) PM/P ND2 Alanine-Threonine;
Alanine-Serine
Edland et al. 2002;
Janetzky et al. 1996; Ko¨sel et al. 1994;
Lin et al. 1992; Petruzzella et al. 1992
8206 (G-T) PM? CO2 Methionine-Isoleucine Qiu et al. 2001
8224 (A-T) PM? CO2 Leucine-Phenylalanine Qiu et al. 2001
16390 (C-T) PM D-LOOP NC Chang et al. 2000
SM, somatic mutation; PM, point mutation; P, polymorphism; NC, non-coding; ND, gene(s) coding for mitochondrial respiratory chain complex I
subunits; CO, gene coding for cytochrome oxidase (COX, complex IV) subunit.
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chance of the mtDNA changes to be a genetic risk factor
comparable with the risk associated to e4 allele, but addi-
tional studies are needed to elucidate this hypothesis.
Nevertheless, Carrieri et al. (2001) have presented a possible
association between mtDNA variations and APO E
genotypes.
It is quite remarkable that the majority of AD patients
presented alterations in the same region of the 16S rRNA
mtDNA gene, suggesting a possible contribution of
mitochondrial 16S rRNA to AD. The functional relevance of
the modifications at rRNA mtDNA genes is still unclear, and
additional studies are needed to elucidate the possible patho-
genic role of rRNA mutations and to clarify the significance of
our finding. As translation mechanisms occur at ribosomes,
rRNA mutations may cause major assembly defects or may
interfere with tRNA protection activity (Noller 1991).
Concerning age of onset, sex, MMSE and CDR data of
patients carrying mtDNA mutations, it was not possible to
establish a correlation with mtDNA analysis. However, it was
possible to observe that AD patients carrying 3197C poly-
morphism presented, in majority of cases, with severe
dementia (54%), as indicated by CDR, and/or cognitive
impairment (69%), scored by MMSE. Apparently, such
alterations in mtDNA do not interfere with cognitive func-
tions. However, in patients with mild cognitive impairment
and/or dementia, it is possible that the patients might have
been evaluated at the beginning of the disease and being
barely unaffected at the time, or other risk factors were
absent in those cases, allowing a slower impairment
progress.
Moreover, both polymorphisms in nucleotide 3197 and in
nucleotide 3338, present in one AD patient, are considered
harmless alone, but the synergistic effect of these altera-
tions or the association to other mitochondrial or nuclear
mutations and polymorphisms is still unknown. It is logical
Table 2: Frequencies of the mtDNA variants A3196G and
T3197C and apolipoprotein E (APO E) alleles in Alzheimer’s dis-
ease (AD) and controls
APO E alleles mtDNA
variants
e2 e3 e4 G3196A T3197C
AD patients 0.028 0.732 0.240** 0.000 0.101*
(n ¼ 129†) (0/129) (13/129)
Control subjects 0.060 0.880 0.060 0.000 0.024
(n ¼ 125) (0/125) (3/125)
AD, Alzheimer’s disease; n, number of individuals; *P < 0.050
**P < 0.0001.
†125 for APO E genotyping.
A 
a   ATCTCAACTTAGTATTATACCCACACCCACCCAAGAACAGGGTTT
b   ATCTCAATTATATATAGCGCCCACATCTACTCAAGAATAGGGTTT
c   ATCTCAATTTAAGCCCATGCCAACACCCACTCAAGAACAGAGTTT
d   ATCTCAATTTAACACCACACCTACACCCACTCAAGAACAGAGTTT
e   ATCTCAATTTAACAC-ACACCAACACCCACCCAAGAAAAGGGTTT
B 
a   ATACCCATGGCCAACCTCCTACTCCTCATTGTACCCATTCTAATCGCAATGGCA
b   ATATCCATGGCTAACCTTCTACTCCTCATTGTACCTATCCTAATCGCCATAGCA
c   ACACCCATGACCAACCTCCTACTCCTCATTGTACCCATCCTAATCGCAATAGCA
d   ACACCCATGACTAACCTCCTACTCCTCATTGTACCTGTCCTAATCGCAATAGCA
e   ATGCCTGTAATCAACCTCCTGCTCCTCACTATATCTATCCTAATCGCCATAGCA
C 
a    MPMANLLLLIVPILIAMAFLMLTERKILGYMQLRKGPNVVGPYG
b    MSMANLLLLIVPILIAMAFLMLTERKILGYMQLRKGPNVVGPYG
c    TPMTNLLLLIVPILIAMAFLMLTERKILGYMQLRKGPNIVGPYG
d    TPMTNLLLLIVPVLIAMAFLMLTERKILGYMQLRKGPNIVGPYG
e    MPVINLLLLTMSILIAMAFLMLTERKILGYTQLRKGPNIVGPCG
Figure 1: Evolutionary conservation among
hominoid primates [Homo sapiens (a),
Gorilla gorilla (b), Pan troglodytes (c), Pan
paniscus (d) and Pongo pygmaeus (e)]. (a)
mtDNA sequence surrounding nucleotides
3196, 3197 and 3199, all underline and bold. (b)
mtDNA sequence surrounding nucleotide 3338,
underline and bold. (c) N-terminal amino acid
sequence of NADH dehydrogenase subunit 1
protein with amino acid coded by nucleotides
3337–3339, underline and bold. Homo sapiens
mtDNA sequence obtained from Anderson et al.
(1981) and Andrews et al. (1999). G. gorilla, P.
troglodytes, P. paniscus and P. pygmaeus
mtDNA sequences obtained from Horai et al.
(1995).
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to think that, as more nucleotide mutations are present in the
mtDNA, higher should be the probability to develop an
energy failure.
It is also possible that distinct combinations of non-
mutated electron transport chain components do not func-
tion identically; being so, non-pathogenic mtDNA variations
could contribute to AD risk while explaining why mtDNA
polymorphism–AD associations are difficult to establish
(Swerdlow & Kish 2002). This idea is supported by a recent
study conducted with PD patients, demonstrating a signifi-
cant decrease in risk of PD patients carrying haplogroup J
(van der Walt et al. 2003). Additionally, Ross et al. (2003)
have also demonstrated that mtDNA variant 4216C (segre-
gates with JT haplogroups cluster) may influence mitochon-
drial dysfunction, affecting MRC complex I activity and
increasing the risk for the disease (Ross et al. 2003). In
Alzheimer’s pathology, an association between mtDNA hap-
logroups and APOE e4 allele has been shown ; in particular,
haplogroups K and U seem to be protective relatively to the
harmful effect of the e4 allele (Carrieri et al. 2001).
We have recently reported for the first time, mtDNA altera-
tions, one already known (3316 G-to-A) and another unre-
ported (3337 G-to-A), and MRC complex I activity reduction
in a frontotemporal dementia patient (Grazina et al. 2004),
reinforcing the involvement of mtDNA alterations in
dementia.
Conclusion
The study of peripheral tissues may be a step forward in
identifying possible genetic risk factors in earlier stages of
AD, allowing earlier therapeutic approaches. Additionally, in
vitro studies performed in fibroblasts (Gibson et al. 1998) and
cybrids (Cardoso et al. 2004b) of AD patients (Kumar et al.
1994) may contribute to clarify the mechanisms underlying
the disease related to mitochondrial genome. It is important
to take into consideration that analysis of mtDNA alterations
should avoid false positives due to nuclear pseudogenes’
detection (Wallace et al. 1997), which might be achieved by
testing polymerase chain reaction primers with rho-0 cells’
DNA.
Additionally, caution is necessary when dealing with
mtDNA, because it has a high mutation rate due to a lack
of a histone coat and an inadequate repair system (Schapira
1994). Given this vulnerability, free radical mtDNA damage
may occur, particularly in ageing and neurodegenerative dis-
orders, causing additional mtDNA injury, possibly initiating a
vicious circle, making the interpretation of these results even
more difficult, and no familial studies to evaluate the mater-
nal heredity are possible in majority of cases.
It has been shown that elevated oxidative damage can be
found in some AD patients, but no direct cause-effect rela-
tionship with mtDNA alterations, including ‘common dele-
tion’, could be established (Bonilla et al. 1999). However, it
has been recently shown that a higher degree of A-b deposi-
tion, overexpression of oxidative stress markers, mtDNA
deletion and mitochondrial structural abnormalities were pre-
sent in the vascular walls of the human AD,YAC and C57B6/
SJLTg(þ) mice compared with age-matched controls (Aliyev
et al. 2005), as well as increased RNA oxidation and COX
immunoreactivity (Aliev et al. 2003).
Although differences in mtDNA heredity may be important
to interpret mtDNA alterations, the restriction of changes to
vulnerable neurons only in cases of AD (shown by Hirai et al.
2001), rather than a more generalized defect involving all cell
types, indicates that mitochondrial inheritance alone is not
the only factor, but probably differences in mitochondrial
turnover and metabolism, as well as antioxidant defences
between different cells, are involved in Alzheimer’s path-
ology (Hirai et al. 2001; Ito et al. 1999).
mtDNA mutations associated to AD may induce different
phenotypic alterations, including functional impairment of the
MRC activity, depending on themetabolic characteristics of the
subject, the individual antioxidant defence panel or the environ-
ment exposure to toxic agents. Accordingly, oxidative stress
resulting frommitochondrial abnormalities, including inmtDNA,
seems to play an important role in AD pathological cascade.
Data reported in literature are controversial, and some
discrepancy exists in the results from different groups, con-
cerning mtDNA alterations. This might be due to several
reasons, going from heterogeneity in the populations and
tissues analysed by different research groups to age of
onset of the disease or mtDNA regions investigated.
Taking into account mitotic segregation, the threshold
effect and individual metabolic status, the moment when
the samples are taken for analysis might influence the
results obtained. Furthermore, different mtDNA regions
have been considered for analysis, using different techni-
ques (for example RFLP vs. sequencing), according to
diverse reports. In addition, the biochemical results of MRC
analysis in AD patients have been mainly directed to complex
IV deficiency (Cardoso et al. 2004a; Parker et al. 1990), but
the involvement of other MRC complexes, namely complex
I, cannot be ruled out. The data reported on Table 1 strongly
suggest that mtDNA genes coding for the subunits of com-
plex I should be further investigated. Actually, the study of
the expression of several mitochondrial and nuclear genes
encoding the subunits of electron transport chain enzyme
complexes showed a coordinated decrease of ND4 mRNA
in AD hippocampus and inferior parietal lobule, probably lead-
ing to the inhibition of normal ubiquinone oxidoreductase
activity of complex I (Aksenov et al. 1999).
It seems unlikely that mtDNA mutations found so far in AD
patients are a genetic risk factor comparable with APO E e4
allele in sporadic AD or APP/PS1,2 mutations in familial
cases. However, the fact that many of the identified
mtDNA mutations are found in patients with neurodegenera-
tive conditions implies that they may contribute to AD (Zhu
et al. 2004).
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The results reported in literature, including those recently
obtained in our laboratory, suggest the contribution of
mtDNA alterations to Alzheimer’s pathology and that
mtDNA alterations in 16S rRNA gene may also account for
some risk in AD.
Furthermore, polymorphic variations in MRC subunits
encoding genes (mtDNA and nDNA) determine MRC effi-
ciency and basal mitochondrial ROS production, which corre-
lates with mtDNA damage. Additionally, somatic mtDNA
mutation decreases MRC efficiency leading to reduced
OXPHOS and/or increased ROS production. Moreover,
mtDNA mutations possibly modify age of onset, contributing
to neurodegeneration process, probably due to an impair-
ment of MRC and/or translation mechanisms.
Moreover, it is difficult to demonstrate a direct link
between the mutant mtDNA genotype and a disease pheno-
type because of incomplete penetrance and the influence of
environmental triggers (Ghosh et al. 1999).
It is likely that mitochondria play a proximal role in the
pathogenesis of the disease and, despite the many known
factors that can contribute to mitochondrial dysfunction at
some time during the disease progression, it still remains to
be determined what initiates the mitochondrial abnormalities
in the disease (Zhu et al. 2004). Nevertheless, some authors
have suggested that the possibility of mitochondrial involve-
ment in AD may be secondary to other pathological events
(Byrne 2002; Orth & Schapira 2001). Currently, it is not clear
whether oxidative damage to mitochondria leads to a
decreased efficiency of the MRC or results in excessive
electron release and ROS formation; in any case, the result
would be a vicious feed-forward cycle where increased
oxidative stress would continually reduce mitochondrial bio-
energetics (Sullivan & Brown 2005).
It has been suggested, in studies with cybrids, that com-
plex IV deficiency described in a majority of AD cases found
in literature may be a primary defect related to the pathology,
rather than a secondary insult that is associated with disease
morbidity (Ghosh et al. 1999). Nevertheless, this issue
remains unclear, and further analyses are required to clarify
the exact role of MRC defects in AD.
The role of mitochondria failure in the pathogenesis of AD
has been widely accepted. However, the exact cellular
mechanisms behind vascular lesions and their relation to
oxidative stress markers identified by RNA/DNA oxidation,
lipid peroxidation or mitochondrial DNA (mtDNA) alterations
remain unknown. Future studies comparing the spectrum of
mitochondrial damage and the relationship to oxidative
stress-induced damage during the maturation of AD path-
ology are warranted (Zhu et al. 2004).
Aiming to reach a comprehensive role of mitochondria in
AD, Swerdlow and Khan (2004) have recently proposed the
‘mitochondrial cascade hypothesis’ for sporadic AD. The
authors suggest that inherited, gene-determined make-up
of an individual’s MRC sets basal rates of ROS production,
potentially relevant to the rate at which mitochondrial
oxidative damage accumulates in an individual over time.
Additionally, oxidative mitochondrial nucleic acid, protein
and lipid damage amplifies ROS production and triggers
events that result in A-b overproduction, further perturbation
of MRC function, abnormal apoptotic responses by the cells,
aneuploidy, tau hyperphosphorylation and NFTs’ formation
(Swerdlow & Khan 2004). Other authors have also suggested
that abnormalities in mtDNA may be a major cause of abnor-
mal ROS production in AD (Migliore et al. 2005), and recent
data provide additional evidence that energy failure may
cause significant changes in both APP expression and APP
metabolism (Hoyer et al. 2005).
Moreover, Swerdlow and Khan (2004) state that this
hypothesis also allows and accounts for histopathologic over-
lap, mediated by bioenergetic dysfunction and mitochondrial
ROS overproduction, between the sporadic, late-onset and
autosomal dominant, early-onset forms of the disease.
Epidemiological studies of AD cases showing a maternal over-
representation among the affected parents (Duara et al. 1993;
Edland et al. 1996) suggest a maternally inherited genetic
factor (mtDNA) that helps to determine life expectancy, as
well as contributing to AD risk (Swerdlow & Khan 2004).
In conclusion, controversial data from literature point to
both directions: one stating that mtDNA mutations are
more likely to be a by-product, secondary to other pathologi-
cal features during the development of the disease; the other
being consistent with the ‘mitochondrial cascade hypo-
thesis’, claiming that mtDNA modifications (both pathogenic
and/or polymorphic) are a cause of the disease.
However, the exact role of mtDNA mutations in AD
remains as a piece of the puzzle on the AD pathological
mechanisms’ enigma, and effective translation of knowledge
of the cellular mechanisms responsible for the disease into
novel therapeutic modalities that may not conform to current
consensus may require a level of dedication and enthusiasm
that allowed Alois Alzheimer to bring forth his invaluable
observations and identification of AD as a defined clinical
entity (Chong et al. 2005).
More to the point, perhaps a key difficulty in the majority
of the experiments published lies in the extent to which one
can ever hope to mimic a disease that might take 70 years to
develop in a tissue-culture dish in an afternoon’s experiment
(Canevari et al. 2004).
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